Saad said there will be a really big uptake, particularly in emerging markets and a lot of new patients on this product because it's affordable and because they will pay out of pocket, while Bloomberg quoted him saying there are so many people that simply cant afford to pay the price of branded products.
Reports of Biochemistry and Molecular Biology 13:507515
Structure Therapeutics Provides Comprehensive GSBR-1290 Program Update Including Clinically Meaningful Proof-of-Concept Data From Phase 2a Clinical Study , (December 18, 2023)
Key Takeaway: If you experience a worsening of "typical" thyroid symptoms after starting a GLP-1, it is usually a sign that your thyroid hormone requirements have changed due to weight loss or absorption shifts
The SURPASS and SURMOUNT trial series are the human pharmacology dataset for tirzepatide
Stacking GHK-Cu: Synergies with Other Peptides and Treatments GHK-Cus efficacy can be amplified when used in combination with other regenerative therapies